Studies with AR antagonists prescribed for prostate cancer treatment (e.g., enzalutamide, apalutamide, and darolutamide) have since shown that SARS-CoV-2 infectivity can be decreased in vitro in certain contexts with these drugs (36, –38). The gene discussed is AR; the disease is prostate cancer.